Now headquartered at the newly opened Translational Clinical Research Center in New York, Roche's Pharma Research & Early Development organization has undergone another retooling intended to increase its efficiency and productivity. The center will enable pRED to access local expertise and patient populations for early human proof-of-concept studies.

On Oct. 1, Roche inaugurated the 250-person Translational Clinical Research Center (TCRC), which will serve as the headquarters for the pharma's clinical operations in the U.S., according to John Reed, the new head of pRED.